With the Nasdaq biotech index proving remarkably resilient to sector-specific and macroeconomic problems alike, smart investors will continue to keep an eye out for signs of panic as a leading indicator of an overall collapse of sentiment. Nothing provides a better guide to the state of play than small and mid-cap companies, whose size makes them particularly exposed to general sector trends.